In a combination arm of CodeBreaK101 trial of sotorasib and trametinib in KRAS G12C-mutant NSCLC and CRC, disease control rate was 67% and 86%, respectively, among patients with prior G12C inhibitor treatment [142]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.